nVision Medical→Boston Scientific
Acquisition · Cash · BSX · announced Apr 16, 2018
Announced
Apr 16, 2018
Closed
Apr 16, 2018
Economics
Cash()
Pre-deal · pre-deal mark: 2018, year precision · Boston Scientific 8-K filing, SEC EDGAR — nVision Medical acquisition
$150M upfront + up to $125M in milestones over 4 years
Target
nVision Medical
Diagnostics · Diagnostic / genomic
HQ San Carlos, CA · Founded 2013
First FDA-cleared device for collecting cells from fallopian tubes — platform for earlier diagnosis of ovarian cancer; $500M near-term market opportunity estimated
- PR Newswire — Boston Scientific press release (Apr 16, 2018)
- MassDevice deal coverage ($275M total)
Acquirer
Boston Scientific (BSX)
Diagnostics
HQ Marlborough, MA
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
First FDA-cleared fallopian tube cell collection device — platform for ovarian cancer early diagnosis; estimated $500M near-term market expanding to $2B
Evidence ladder
Secondary (press / IR)
PR Newswire — Boston Scientific press release (Apr 16, 2018)
Tertiary (trade / analyst)
MassDevice deal coverage
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/885725/000088572518000019/q12018earningsrelease.htm
Open source
Limitations
- $150M upfront + up to $125M in milestones over 4 years
- Pre-deal valuation sourced from: Boston Scientific 8-K filing, SEC EDGAR — nVision Medical acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Alere | Abbott Laboratories | Feb 1, 2016 | ||
| Thrive Earlier Detection | Exact Sciences | Oct 27, 2020 | ||
| Igenomix | Vitrolife | Jul 8, 2021 | ||
| EUROIMMUN | PerkinElmer (Revvity) | Jun 16, 2017 |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — nVision Medical (Diagnostics). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.